KALA BIO, Inc. (KALA)

6,71 -0,21 (-2,99%) Börsenschluss: 04:00PM EDT

KALA BIO, Inc.

1167 Massachusetts Avenue
Arlington, MA 02476
United States
781 996 5252
https://www.kalarx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 43

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Mark T. Iwicki	Chairman & CEO	1,01M	N/A	1966
Mr. Todd Bazemore	President & COO	733,58k	N/A	1970
Dr. Kim Brazzell Ph.D.	Head of R&D and Chief Medical Officer	709,49k	N/A	1953
Dr. Justin Hanes Ph.D.	Founder & Chair of the Scientific Advisory Board	N/A	N/A	N/A
Ms. Mary Reumuth CPA	CFO & Treasurer	N/A	N/A	1975
Ms. Jill S. Steier	Executive Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	N/A	N/A	1963
Mr. Darius Kharabi J.D., M.B.A.	Chief Business Officer	N/A	N/A	1980
Dr. Francis S. Mah M.D.	Chief Medical Advisor	N/A	N/A	N/A
Mr. Josiah Craver	Senior VP & Corporate Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Corporate Governance

KALA BIO, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.